Modalis Therapeutics (TSE:4883) Total Stockholders Equity: 円2,473.37 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:4883 Modalis Therapeutics Corp TSE:4883
20 GF Score
Price 円33.00
! 2 Warning Signs
View Full Analysis

What is Modalis Therapeutics Total Stockholders Equity?

Modalis Therapeutics TSE:4883 +3.13% 20 Total Stockholders Equity is 円2,473.37 Mil as of Jun. 2026. GuruFocus rates TSE:4883 with a GF Score™ of 20/100. The stock has 2 warning signs investors should review.

Modalis Therapeutics's Total Stockholders Equity for the quarter that ended in Jun. 2026 was 円2,473.37 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Modalis Therapeutics's Book Value per Share for the quarter that ended in Jun. 2026 was 円25.41. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Modalis Therapeutics's Debt-to-Equity for the quarter that ended in Jun. 2026 was 0.11.

Modalis Therapeutics  (TSE:4883) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Modalis Therapeutics's Book Value per Share for the quarter that ended in Jun. 2026 is

Book Value per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(2473.372-0)/97.334034
=25.41

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Modalis Therapeutics's Debt-to-Equity for the quarter that ended in Jun. 2026 is

Debt-to-Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(270 + 0) / 2473.372
=0.11

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Modalis Therapeutics Total Stockholders Equity Related Terms

Modalis Therapeutics Total Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Modalis Therapeutics's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Modalis Therapeutics Total Stockholders Equity Chart

Modalis Therapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Stockholders Equity
Get a 7-Day Free Trial 5,549.21 2,941.23 1,380.42 3,548.08 2,793.30

Modalis Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Total Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3,187.50 2,693.63 2,793.30 2,799.75 2,473.37
TSE:4883
20GF Score
Modalis Therapeutics Corp TSE:4883
Total Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Total Stockholders Equity of 円2,473.37 Mil mean?
Modalis Therapeutics (TSE:4883) has a Total Stockholders Equity of 円2,473.37 Mil as of Jun. 2026. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Modalis Therapeutics and its competitors.
Is Modalis Therapeutics' Total Stockholders Equity too high?
Modalis Therapeutics' current Total Stockholders Equity is 円2,473.37 Mil. Overall, Modalis Therapeutics has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Modalis Therapeutics' Total Stockholders Equity compare to ZTS and UTHR?
Modalis Therapeutics' Total Stockholders Equity of 円2,473.37 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Stockholders Equity for a Drug Manufacturers company?
A good Total Stockholders Equity depends on the Drug Manufacturers industry context. However, Total Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Stockholders Equity mean?
A high Total Stockholders Equity can signal that a stock is expensive relative to its fundamentals. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Modalis Therapeutics and its competitors. Modalis Therapeutics's current Total Stockholders Equity is 円2,473.37 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Modalis Therapeutics stock overvalued right now?
Modalis Therapeutics (TSE:4883) has a current Total Stockholders Equity of 円2,473.37 Mil. The current Total Stockholders Equity is 円2,473.37 Mil. Modalis Therapeutics' overall GF Score™ is 20/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Stockholders Equity calculated?
Total Stockholders Equity is calculated from a company's financial statements. For Modalis Therapeutics (TSE:4883), the current Total Stockholders Equity is 円2,473.37 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Modalis Therapeutics Business Description

Address 3-11-5 Nihonbashi Honcho, Chuo-ku, Tokyo, JPN, 103-0026
Modalis Therapeutics Corp is a drug development company. It is engaged in research and development of Gene Therapy using core platform technology, non-editing CRISPR technology (CRISPR-GNDM). The company's products in the pipeline are MDL-201, MDL-202, MDL-204, MDL-205, MDL-206, MDL-101, and MDL-102.
20GF Score

Get the complete analysis for TSE:4883

Total Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円33.00
Price